Ipeleng Kgosiemang-Xaba | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Ipeleng Kgosiemang-Xaba
University of the Free State, South Africa
Ipeleng Kgosiemang-Xaba
Affiliation University of the Free State
Country South Africa
Scopus ID 56707418000
Documents 9
Citations 241
h-index 7
Subject Area Oncology
Event Health Scientists Awards

Ipeleng Kgosiemang-Xaba is presented in this academic recognition profile as a researcher associated with oncology and biomedical research at the University of the Free State in South Africa. Her scholarly work includes investigations of Euphorbia species, phytochemicals, antiproliferative activity, nanomaterials, and cancer-related applications. Publications identify research examining plant-derived compounds, toxicity, pharmacological properties, and nanoparticle-based approaches against breast cancer models. This work connects natural-product research with experimental oncology and drug-discovery questions.[1]

Abstract

Ipeleng Kgosiemang-Xaba is presented in this recognition profile as a researcher associated with oncology and biomedical research at the University of the Free State in South Africa. Her scholarly work includes investigations of Euphorbia species, phytochemicals, antiproliferative activity, nanomaterials, and cancer-related applications. Publications identify research examining plant-derived compounds, toxicity, pharmacological properties, and nanoparticle-based approaches against breast cancer models. This work connects natural-product research with experimental oncology and drug-discovery questions. The profile therefore highlights an interdisciplinary trajectory centered on biologically active South African plants, cancer-related mechanisms, and translational opportunities while maintaining a neutral distinction between documented scientific outputs and award recognition.[3]

Keywords

Euphorbia species; cancer; medicinal plants; pharmacological properties; toxicity; secondary metabolites; breast cancer; antiproliferative activity; iron oxide nanoparticles; iron dioxide nanoparticles; natural-product pharmacology; phytochemicals. These terms are aligned particularly with the publication literature addressing Southern African Euphorbia species and experimental anticancer research.[2]

Introduction

Ipeleng Kgosiemang-Xaba’s research profile reflects an interdisciplinary interest in oncology, medicinal plants, pharmacology, and biomedical technology. Her publications address Euphorbia-derived bioactive compounds and experimental anticancer approaches, including nanoparticle systems evaluated against breast cancer cell lines. These themes place natural-product research within a framework of cancer research and translational biomedical investigation.[1]

Research Profile

Ipeleng Kgosiemang-Xaba has published work spanning molecular biology, medicinal plants, phytochemistry, pharmacology, and oncology. Her research includes studies of Euphorbia species and their secondary metabolites, together with experimental investigations of antiproliferative effects and nanoparticle-mediated approaches. The available literature indicates a continuing interest in linking biological resources with therapeutic research questions.[2][3]

Research Contributions

Ipeleng Kgosiemang-Xaba’s contributions include systematic examination of Southern African Euphorbia species, their medicinal uses, toxicity, phytochemical constituents, and reported pharmacological activities. Her research also includes green synthesis of iron-based nanoparticles using Euphorbia tirucalli and evaluation of antiproliferative activity against breast cancer cell lines, thereby connecting plant science with experimental oncology.[2][3]

Publications

Ipeleng Kgosiemang-Xaba is associated with publications addressing Euphorbia pharmacology, anticancer research, nanoparticle synthesis, and molecular biology. A 2025 review in Plants examined medicinal uses, toxicity, secondary metabolites, and pharmacological properties of Southern African Euphorbia species, while a 2023 Journal of Experimental Nanoscience article evaluated iron-based nanoparticles and breast cancer models.[5]

Research Impact

Ipeleng Kgosiemang-Xaba’s research impact can be considered through the relevance of her publications to natural-product pharmacology, cancer biology, and biomedical nanotechnology. Her work contributes evidence on underexplored Southern African plant resources and experimental anticancer strategies. Citation activity and publication visibility provide measurable indicators, while broader clinical significance requires further validation.[3]

Award Suitability

Ipeleng Kgosiemang-Xaba’s documented research themes are compatible with an Innovative Research Award focused on oncology, natural-product discovery, and biomedical technology. Her publications demonstrate research activity involving anticancer constituents, Euphorbia species, phytochemicals, and nanoparticle systems. Award suitability should remain subject to the event’s published formal criteria, independent verification, and comparative assessment.[4]

Conclusion

Ipeleng Kgosiemang-Xaba presents a research profile connecting Southern African medicinal plants with pharmacology, nanotechnology, and oncology. Her publications provide evidence of work on Euphorbia chemistry, toxicity, antiproliferative activity, and cancer-oriented experimental systems. Collectively, these outputs support recognition of an emerging interdisciplinary research direction without implying clinical efficacy beyond published evidence.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Ipeleng Kgosiemang-Xaba, Author ID 56707418000. Scopus.https://www.scopus.com/authid/detail.uri?authorId=56707418000
  2. Kgosiemang, I. K. R., Lefojane, R., Adegoke, A. M., Ogunyemi, O., Mashele, S. S., & Sekhoacha, M. P. (2025). Pharmacological significance, medicinal use, and toxicity of extracted and isolated compounds from Euphorbia species found in Southern Africa: A review. Plants, 14(3), 469.https://doi.org/10.3390/plants14030469
  3. Kgosiemang, I. K. R., Adegoke, A. M., Mashele, S. S., & Sekhoacha, M. P. (2023). Green synthesis of iron oxide and iron dioxide nanoparticles using Euphorbia tirucalli: Characterization and antiproliferative evaluation against three breast cancer cell lines. Journal of Experimental Nanoscience, 18(1), 2276276.https://doi.org/10.1080/17458080.2023.2276276
  4. Parvez, M., Qhanya, L. B., Mthakathi, N. T., Kgosiemang, I. K. R., et al. (2016). Molecular evolutionary dynamics of cytochrome P450 monooxygenases across kingdoms: Special focus on mycobacterial P450s. Scientific Reports, 6, 33099.https://doi.org/10.1038/srep33099
  5. Kgosiemang, I. K. R. (2024). Targeted delivery of iron, cobalt and magnesium nanoparticles incorporating anticancer constituents of Euphorbia species for treatment of breast cancer. Doctor of Health Sciences in Biomedical Technology, Central University of Technology, Free State.https://cutscholar.cut.ac.za/items/e527142e-a8dc-4c94-8eb1-121facf1eff7/full

Aimaz Afrough | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Aimaz Afrough
UT Southwestern Medical Center, United States

Aimaz Afrough
Affiliation UT Southwestern Medical Center
Country United States
Scopus ID 43660943000
Documents 63
Citations 1,171
h-index 19
Subject Area Oncology
Event Health Scientists Awards
ORCID 0000-0003-2645-8557

Aimaz Afrough is a researcher affiliated with UT Southwestern Medical Center whose scholarly work primarily focuses on oncology, molecular cancer biology, translational medicine, and clinically relevant cancer investigations. The research portfolio reflects sustained contributions to understanding tumor biology, improving diagnostic approaches, and supporting evidence-based therapeutic development. Publications indexed in major scientific databases demonstrate active participation in multidisciplinary cancer research while promoting scientific collaboration and clinical translation within contemporary oncology research.[1]

Abstract

Aimaz Afrough investigates oncology through multidisciplinary research integrating molecular biology, translational medicine, cancer diagnostics, and therapeutic innovation. Published studies emphasize clinically meaningful discoveries that improve understanding of tumor development, disease progression, biomarker identification, and treatment response. The research demonstrates collaboration across biomedical disciplines while supporting evidence-based clinical practice and precision oncology. Scientific publications indexed in recognized databases contribute to advancing cancer research, strengthening translational applications, encouraging interdisciplinary collaboration, and providing valuable knowledge that informs future investigations, patient-centered healthcare strategies, and sustainable improvements in oncology outcomes worldwide.[2]

Keywords

Oncology, Cancer Biology, Tumor Microenvironment, Precision Oncology, Molecular Oncology, Cancer Biomarkers, Translational Medicine, Immuno-Oncology, Clinical Oncology, Cancer Therapeutics

Introduction

Aimaz Afrough contributes to oncology research by investigating biological mechanisms underlying cancer and translating laboratory discoveries into clinically meaningful knowledge. Research activities strengthen interdisciplinary collaboration while supporting innovative diagnostic methods, precision medicine, and therapeutic development that improve understanding of complex malignancies across diverse healthcare environments.[3]

Research Profile

Aimaz Afrough maintains an academic profile centered on oncology, emphasizing molecular mechanisms, translational investigations, biomarker discovery, and collaborative biomedical research. Publications demonstrate commitment to scientific rigor while addressing clinically relevant questions that support evidence generation and continuous advancement of modern cancer research and healthcare innovation.[1]

Research Contributions

Aimaz Afrough has contributed to collaborative investigations exploring cancer biology, translational oncology, molecular diagnostics, and therapeutic strategies. Research findings enhance scientific understanding of disease mechanisms while supporting precision medicine initiatives, improving clinical interpretation, and encouraging continued innovation across multidisciplinary oncology research communities worldwide.[4]

Publications

Aimaz Afrough has authored and coauthored peer-reviewed publications indexed within recognized scientific databases. Published studies address oncology, molecular medicine, and translational research while reflecting sustained scholarly engagement, interdisciplinary collaboration, methodological quality, and contributions supporting scientific communication, clinical relevance, and future biomedical investigation.[2]

Research Impact

Aimaz Afrough demonstrates measurable research impact through scholarly publications, scientific collaborations, and dissemination within oncology. The research supports evidence-based medicine, encourages knowledge exchange, informs future investigations, and contributes valuable insights that strengthen translational cancer research and broader biomedical scientific advancement internationally.[1]

Award Suitability

Aimaz Afrough demonstrates qualifications appropriate for consideration within the Innovative Research Award through consistent oncology research, interdisciplinary collaboration, scholarly publications, and contributions supporting translational medicine. Scientific activities reflect innovation, academic integrity, and continuing commitment to advancing biomedical knowledge through evidence-based cancer research.[5]

Conclusion

Aimaz Afrough continues contributing to oncology through collaborative scientific research emphasizing translational relevance, molecular discoveries, and clinical applicability. Continued scholarly activities strengthen biomedical knowledge, encourage innovation, support evidence-based healthcare, and provide meaningful foundations for future advances within international oncology research communities.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Aimaz Afrough, Author ID 43660943000. Scopus.
    https://www.scopus.com/pages/authors/43660943000
  2. ORCID. (n.d.). Aimaz Afrough ORCID Record.
    https://orcid.org/0000-0003-2645-8557
  3. Google Scholar. (n.d.). Scholar Profile: Aimaz Afrough.
    https://scholar.google.com/citations?user=2ENlGnkAAAAJ&hl=en&oi=ao
  4. ResearchGate. (n.d.). Aimaz Afrough Research Profile.
    https://www.researchgate.net/profile/Aimaz-Afrough
  5. Health Scientists Awards. (n.d.). Innovative Research Award.
    https://healthscientists.org/

Bina Kashyap | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Bina Kashyap
Agartala Government Dental College, India

Bina Kashyap
Affiliation Agartala Government Dental College
Country India
Scopus ID 39561184400
Documents 28
Citations
389
h-index
11
Subject Area Oncology
Event Health Scientists Awards
ORCID 0000-0001-9192-8645

Bina Kashyap is an academic researcher affiliated with Agartala Government Dental College, India. Her scholarly work contributes to oncology-related oral health research, emphasizing clinical dentistry, oral pathology, cancer prevention, and evidence-based healthcare. Through peer-reviewed scientific publications, she has participated in advancing understanding of oral diseases associated with malignancy and related diagnostic approaches. Her research activities demonstrate continued engagement with interdisciplinary healthcare investigations and provide meaningful contributions to dental oncology literature.[1]

Abstract

Bina Kashyap has developed an academic profile centered on oncology-related oral healthcare, integrating clinical dentistry with evidence-based scientific investigation. Her published studies contribute to understanding oral manifestations associated with cancer, diagnostic evaluation, pathology, preventive strategies, and multidisciplinary patient management. Through collaboration with healthcare professionals and academic researchers, her work supports improved clinical decision-making and encourages continual advancement in dental oncology research. The consistency of her scholarly contributions, institutional affiliation, and participation in peer-reviewed scientific communication collectively demonstrate sustained professional engagement within oncology and oral health sciences, reflecting recognized standards of academic research excellence.[1][2]

Keywords

Oral Oncology, Oral Cancer, Oral Pathology, Dental Oncology, Precancerous Lesions, Oral Medicine, Clinical Dentistry, Histopathology, Cancer Diagnosis, Public Health Dentistry.

Introduction

Bina Kashyap contributes to oncology research through dental science by examining oral diseases, pathological conditions, diagnostic practices, and preventive healthcare. Her academic publications strengthen interdisciplinary collaboration between dentistry and medicine while supporting evidence-based clinical management and improved patient outcomes across oral healthcare settings.[2]

Research Profile

Bina Kashyap maintains an active scholarly profile through peer-reviewed publications indexed in international databases. Her affiliation with Agartala Government Dental College reflects continuing involvement in academic research, clinical education, and collaborative scientific activities related to oncology, oral pathology, and dental healthcare advancement.[1]

Research Contributions

Bina Kashyap has contributed to scientific understanding by investigating oral pathological conditions, cancer-related lesions, diagnostic approaches, and preventive dental practices. Her collaborative research encourages evidence-based treatment planning while supporting broader awareness regarding early detection and multidisciplinary management within oral oncology research.[3]

Publications

Bina Kashyap has authored and co-authored peer-reviewed publications addressing oral oncology, oral pathology, dental diagnostics, and associated healthcare topics. Her scholarly articles appear within recognized academic journals, contributing validated scientific evidence that supports clinical practice, education, and future interdisciplinary research developments.[2]

Research Impact

Bina Kashyap demonstrates measurable academic influence through internationally indexed publications that support evidence-based dentistry and oncology research. Her scientific output contributes valuable knowledge for clinicians, educators, and researchers while promoting continuous improvement in diagnostic accuracy, patient care, and interdisciplinary healthcare collaboration.[1]

Award Suitability

Bina Kashyap demonstrates qualifications consistent with recognition through the Innovative Research Award by maintaining scholarly productivity, contributing oncology-related dental research, encouraging collaborative scientific inquiry, and supporting clinical advancement. Her academic record reflects commitment to research quality, professional integrity, and healthcare innovation.[4]

Conclusion

Bina Kashyap represents a dedicated academic researcher whose work integrates dentistry with oncology through scientifically validated investigation. Her publications, institutional engagement, and commitment to evidence-based healthcare collectively support continued professional recognition while encouraging future advancements in oral cancer research and clinical practice.[1]

External Links

References

  1. Elsevier. (n.d.). Scopus author details: Bina Kashyap, Author ID 39561184400. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=39561184400
  2. ORCID. (n.d.). Bina Kashyap – ORCID Research Profile.
    https://orcid.org/0000-0001-9192-8645
  3. Soiniemi, L., Kanniainen, M., Suomela, E., Ramsay, S., Jäsberg, H., Kashyap, B., & Kullaa, A. M. (n.d.). Transmembrane mucin 1 is a polarity protein in the organization of apical surface microplicae in oral epithelium. https://pubmed.ncbi.nlm.nih.gov/41146464/
  4. Ramsay, S., Hyvärinen, E., Mikkonen, J., González-Arriagada, W. A., Salo, T., Lopes, M. A., Kashyap, B., & Kullaa, A. M. (n.d.). Salivary metabolite-based prediction of radiotherapy-induced oral mucositis and candidiasis. https://pubmed.ncbi.nlm.nih.gov/41372697/
  5. Kashyap, B., Naumanen, K., Mikkonen, J., Dekker, H., Schulten, E., Bloemena, E., Pasonen-Seppänen, S., & Kullaa, A. (n.d.). Irradiation alters the expression of MUC1, CD44 and hyaluronan in oral mucosal epithelium. https://doi.org/10.3390/biomedicines10112816

Khadijeh Dizaji Asl | Oncology | Editorial Board Member

Published on by Health Scientists

Editorial Board Member

Khadijeh Dizaji Asl
Islamic Azad University, Iran

                        Khadijeh Dizaji Asl
Affiliation Islamic Azad University
Country Iran
Scopus ID 57221391321
Documents 21
Citations 207
h-index 8
Subject Area Oncology
Event Health Scientists Awards
ORCID 0000-0003-0920-9583

Khadijeh Dizaji Asl is an oncology-focused researcher affiliated with Islamic Azad University, Iran. Her scholarly activities contribute to the advancement of cancer-related research, clinical understanding, and evidence-based scientific inquiry. Through publications indexed in major academic databases and an established citation record, she has demonstrated sustained engagement with oncology research and interdisciplinary scientific collaboration.[1][2]

Abstract

Khadijeh Dizaji Asl is an oncology researcher affiliated with Islamic Azad University whose scholarly record reflects active participation in cancer-related investigations and biomedical research. Her publications address topics associated with oncology, disease mechanisms, clinical outcomes, and evidence-based healthcare approaches. Indexed academic outputs, citation performance, and an established h-index indicate measurable scientific visibility within her research field. Through collaboration, publication, and dissemination of findings, she contributes to the broader understanding of oncological challenges and supports the development of knowledge that informs future research directions and clinical applications in cancer science.[1][2]

Keywords

Oncology, Cancer Research, Clinical Oncology, Biomedical Science, Tumor Biology, Medical Research, Health Sciences, Evidence-Based Medicine, Cancer Studies, Scientific Publications

Introduction

Khadijeh Dizaji Asl has developed a research profile centered on oncology and related biomedical disciplines. Her scholarly work contributes to the growing body of scientific literature addressing cancer mechanisms, treatment perspectives, and healthcare outcomes. Academic indexing and citation metrics demonstrate continued engagement with internationally visible research activities.[1]

Research Profile

Affiliated with Islamic Azad University, Khadijeh Dizaji Asl has authored publications indexed in Scopus and other academic platforms. Her research interests primarily involve oncology-related investigations, scientific collaboration, and dissemination of evidence supporting advancements in cancer research and healthcare knowledge.[1][2]

Research Contributions

Her scholarly contributions include participation in studies that enhance understanding of oncological processes and clinical implications. Through peer-reviewed publications, she has supported scientific discussion surrounding cancer research, contributing data and analyses that strengthen evidence-based approaches within the field.[1][3]

Publications

The publication portfolio of Khadijeh Dizaji Asl includes twenty-one indexed documents with measurable citation performance. Her research outputs appear within recognized scholarly channels and contribute to the dissemination of oncology-focused findings relevant to researchers, clinicians, and healthcare stakeholders.[1]

Research Impact

With more than two hundred citations and an h-index of eight, her work demonstrates scholarly recognition within the scientific community. These indicators suggest that published findings have informed subsequent studies and contributed to ongoing academic discourse in oncology research.[1][2]

Award Suitability

Based on her documented research productivity, citation record, and commitment to oncology scholarship, Khadijeh Dizaji Asl demonstrates qualifications aligned with recognition programs that value scientific contribution, academic engagement, and advancement of health-related research within the international research community.[4]

Conclusion

Khadijeh Dizaji Asl has established a visible academic presence through oncology-focused research, indexed publications, and scholarly citations. Her contributions support scientific understanding of cancer-related topics and reflect ongoing participation in research activities that advance evidence-based knowledge and healthcare scholarship.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Khadijeh Dizaji Asl, Author ID 57221391321. Scopus.https://www.scopus.com/authid/detail.uri?authorId=57221391321
  2. ORCID. (n.d.). Khadijeh Dizaji Asl: ORCID record 0000-0003-0920-9583.https://orcid.org/0000-0003-0920-9583
  3. Google Scholar. (n.d.). Scholar profile of Khadijeh Dizaji Asl.https://scholar.google.com/citations?user=fyQaW6YAAAAJ&hl=en&oi=ao
  4. ResearchGate. (n.d.). Khadijeh Dizaji Asl researcher profile.https://www.researchgate.net/profile/Khadijeh-Dizaji-Asl

Dimitrios Bouklas | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Dimitrios Bouklas
General Hospital of Athens “G. Gennimatas”
          Dimitrios Bouklas
Affiliation General Hospital of Athens “G. Gennimatas”
Country Greece
Scopus ID 57372362800
Documents 5
Citations 2
h-index 1
Subject Area Oncology
Event Health Scientists Awards
ORCID 0000-0002-5858-0357

Dimitrios Bouklas is affiliated with the General Hospital of Athens “G. Gennimatas” in Greece and contributes to oncology-related clinical and scientific investigations. His scholarly profile demonstrates engagement in cancer research and healthcare studies, supported by indexed publications and citation records available through international academic databases.[1][2]

Abstract

Dimitrios Bouklas has developed a research profile focused on oncology and clinical healthcare studies within a hospital-based environment. His published work contributes to understanding cancer-related conditions, patient management approaches, and evidence-based medical practice. Indexed publications demonstrate participation in multidisciplinary scientific investigations and collaboration with healthcare professionals. Through dissemination of peer-reviewed research, his work supports ongoing efforts to improve clinical knowledge and patient outcomes. The available scholarly metrics, including indexed documents, citations, and author identifiers, indicate active engagement in scientific communication and contribution to contemporary oncology literature and healthcare research initiatives.[1][2]

Keywords

Oncology, Cancer Research, Clinical Oncology, Healthcare Research, Medical Science, Hospital-Based Research, Cancer Care, Clinical Studies, Patient Outcomes, Scientific Publications

Introduction

The advancement of oncology relies on continuous clinical investigation and evidence-based practice. Dimitrios Bouklas contributes to this field through participation in research activities associated with cancer care, clinical assessment, and healthcare improvement, supporting scientific understanding and the translation of research findings into medical practice.[1]

Research Profile

His academic profile is represented through indexed publications in oncology and related healthcare disciplines. Affiliated with a major healthcare institution in Greece, he participates in scientific studies addressing clinical challenges, patient care considerations, and disease-related investigations within contemporary medical research environments.[1][2]

Research Contributions

Dimitrios Bouklas has contributed to peer-reviewed investigations involving oncology-focused clinical research. His work supports scientific discussion on disease management, healthcare outcomes, and multidisciplinary medical collaboration. These contributions enhance the evidence base available to clinicians and researchers working in cancer-related healthcare settings.[1]

Publications

The researcher’s publication record includes indexed scientific articles documented within Scopus and other scholarly platforms. These works reflect involvement in oncology and clinical medicine research, contributing to the dissemination of healthcare knowledge through peer-reviewed academic literature and professional scientific communication.[1][3]

Research Impact

Research impact is reflected through citation activity, indexed publications, and professional visibility across scholarly databases. Although at an early citation stage, the documented work contributes to oncology literature and supports ongoing academic engagement within clinical and healthcare research communities.[1][4]

Award Suitability

Dimitrios Bouklas demonstrates qualifications aligned with the objectives of the Innovative Research Award through documented scholarly activity, oncology-focused investigations, and participation in scientific publication. His commitment to advancing clinical knowledge and supporting evidence-based healthcare makes him a relevant candidate for academic recognition.[1][2]

Conclusion

The academic profile of Dimitrios Bouklas reflects meaningful engagement in oncology research and scientific communication. Through publications, institutional affiliation, and participation in healthcare studies, he contributes to the advancement of medical knowledge and demonstrates characteristics consistent with emerging research excellence.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Dimitrios Bouklas, Author ID 57372362800. Scopus.

    https://www.scopus.com/authid/detail.uri?authorId=57372362800

  2. ORCID. (n.d.). Dimitrios Bouklas – ORCID Record.

    https://orcid.org/0000-0002-5858-0357

  3. ResearchGate. (n.d.). Dimitrios Bouklas Research Profile and Publications.

    https://www.researchgate.net/profile/Dimitrios-Bouklas

  4. Google Scholar. (n.d.). Dimitrios Bouklas Citation Profile.

    https://scholar.google.com/citations?user=h6mhYUIAAAAJ&hl=en&oi=ao

Lingyu Ding | Oncology | Distinguished Scientist Award

Published on by Health Scientists

Mrs. Lingyu Ding | Oncology | Distinguished Scientist Award

clinical nurse | Jiangsu province hospital | China

Lingyu Ding is a distinguished registered nurse at the Colorectal Surgery Department of The First Affiliated Hospital with Nanjing Medical University, specializing in oncology nursing, perioperative rehabilitation, and cancer-related frailty. She has made significant contributions to the development and validation of frailty assessment models for cancer survivors and has designed and pilot-tested multimodal interventions to manage frailty, demonstrating a strong commitment to improving patient outcomes. Her research has been published extensively in peer-reviewed journals, encompassing systematic reviews, meta-analyses, and observational studies that explore preoperative frailty, sedentary behavior, handgrip strength asymmetry, and postoperative outcomes among older adults with cancer. Lingyu has successfully secured and led a project funded by the National Natural Science Foundation of China, reflecting her leadership and research capabilities, and she actively engages in collaborative projects with multidisciplinary teams. Her work has been recognized with prestigious awards for excellence in professional practice, innovative nursing interventions, and outstanding young talent, underscoring both her academic and clinical impact. Beyond her research, Lingyu contributes to the scholarly community as a peer reviewer for international journals, ensuring the rigor and quality of scientific publications. Her expertise spans both quantitative and qualitative research methodologies, including randomized controlled trials, questionnaire design, phenomenological research, and grounded theory, complemented by proficiency in statistical analysis and academic writing. Through her clinical practice, research, and scholarly activities, Lingyu Ding advances the understanding and management of frailty in cancer patients, bridging the gap between evidence-based research and practical healthcare applications, and making a meaningful impact on patient care, health outcomes, and the broader field of oncology nursing. She has 361 citations from 33 documents with an h-index of 11.

Profile: Scopus 

Featured Publications

1. Willingness, preference, and resistance to frailty intervention for older gastric cancer based on stakeholder perspective: A qualitative study. (2025). BMC Geriatrics. Open access.

2. Clinical characteristics and correlation between preoperative frailty and metabolic syndrome among older patients with gastric cancer. (2025). Chinese General Practice.

3.BMI trajectories, associations with outcomes and predictors in elderly gastric cancer patients undergoing radical gastrectomy: A prospective longitudinal observation study. (2025). Journal of Cancer Survivorship.

Rasha Elsabagh | Oncology | Research Excellence Award

Published on by Health Scientists

Dr. Rasha Elsabagh | Oncology | Research Excellence Award

Researcher | Animal Health Research Institute(AHRI) | Egypt

Rasha H. Elsabagh is a multidisciplinary immunology specialist and cancer stem cell researcher with extensive expertise spanning stem cell biology, immuno-oncology, translational cancer research, and veterinary biomedical sciences. She currently serves as a researcher at the Animal Health Research Institute, where her work integrates advanced immunological diagnostics, molecular biology, and national livestock immunization programs that directly contribute to animal health surveillance and disease control. Her academic training culminated in a doctoral degree in cancer immunology from Cairo University, where her research focused on circulating cancer stem cells and photothermal nanotherapy as predictive and monitoring tools for tumor response. She has conducted advanced international research training at University of California San Francisco, gaining high-level proficiency in flow cytometry, immunofluorescence, and human stem cell analysis, and later expanded her translational oncology experience as a visiting research fellow at the Cancer Institute of Montpellier, working on nanoparticle-mediated RNA delivery to tumor-infiltrating immune cells. Her scientific output includes multiple peer-reviewed publications in high-impact journals and international conference proceedings, with her work receiving sustained scholarly citations and global academic recognition. Her research collaborations span institutions in North America, Europe, and the Middle East, reflecting her active role in international scientific networks in stem cell biology, cancer immunology, and nanomedicine. Beyond laboratory research, she contributes to national capacity building through scientific training, quality assurance in diagnostic immunology, and public health–oriented animal disease control programs. Her work has direct societal impact through improvements in cancer diagnostics, advancement of immunotherapeutic strategies, and strengthening of zoonotic disease surveillance, positioning her as a globally engaged scientist at the intersection of experimental research, translational medicine, and public health. She has 2 citations from 2 documents with an h-index of 1.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Xiao, T., Eze, U. C., Charruyer-Reinwald, A., Weisenberger, T., Khalifa, A., … (2024). Short cell cycle duration is a phenotype of human epidermal stem cells. Stem Cell Research & Therapy, 15(1), 76.

2. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Ragab, E., … (2021). Quantitative flow cytometry assessment of feline circulatory breast cancer stem cells. Advances in Animal and Veterinary Sciences, 9(12), 2201–2215.

3. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Abdelrahman, H. H., Ragab, E., … (2025). Gold nano-rod (AuNR)-mediated plasmonic photothermal therapy in feline mammary carcinoma: Assessing metastatic and nonmetastatic outcomes. Veterinary Oncology, 2(1), 33.

4. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Abdelrahman, H., Ragab, E., … (2022). Prevention of in situ recurrence and distant metastasis in feline mammary carcinoma treated with plasmonic photothermal therapy.

 

Niladry Sekhar Ghosh | Oncology | Best Researcher Award

Published on by Health Scientists

Prof. Niladry Sekhar Ghosh | Oncology | Best Researcher Award

Professor | Assam Down Town University, Guwahati | India

Prof. Niladry Sekhar Ghosh is a distinguished researcher and Professor at Assam Down Town University, Guwahati, serving also as Member Secretary of the Board of Studies, with extensive expertise in pharmaceutical sciences, medicinal chemistry, and biomedical research. He earned his B.Pharm. and M.Pharm. degrees from S.C.S College of Pharmacy, R.G.U.H.S Bangalore, graduating with first-class honors, and completed his Ph.D. at Shobhit University in 2020, focusing on the synthesis of bioactive fluoro-benzothiazole derivatives and the biosynthesis of metallic nanoparticles for biological and pharmacological screening. With over 18 years of teaching experience and significant contributions to research, his key areas of interest include drug discovery, medicinal chemistry, nanotechnology-based drug delivery systems, pharmacological evaluation of bioactive compounds, and cancer therapeutics. Prof. Ghosh has authored more than 50 publications in high-impact journals indexed in SCI, Scopus, and ESCI, including studies on cathepsin inhibitors, benzimidazole and indole derivatives as anticancer agents, and green synthesis of nanoparticles. He has been recognized with multiple honors, notably the Young Teacher Awards by SPER in 2016 and 2018, and has secured competitive research grants from SERB-DST, DBT, ICMR, and NCW for innovative projects in pharmaceutical biotechnology and nanomedicine. Additionally, he holds patents for metallic nanoparticle synthesis and biomedical devices. Beyond research, he serves as a resource person, reviewer, and editor for various scientific journals, contributing to the dissemination of knowledge in medicinal chemistry, pharmacology, and nanotechnology. His leadership roles in academic administration and research guidance underscore his commitment to advancing pharmaceutical education and translational research. He has 90 citations from 22 documents with an h-index of 7.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Dubey, A., Ghosh, N. S., & Singh, R. (2022). Zebrafish as an emerging model: An important testing platform for biomedical science.

2. Dubey, A., Ghosh, N. S., Gupta, A., & Singh, S. (2023). A review on current epidemiology and molecular studies of lumpy skin disease virus—An emerging worldwide threat to domestic animals.

3. Dubey, A., Ghosh, N. S., Agnihotri, N., Kumar, A., Pandey, M., & Nishad, S. (2022). Herbs derived bioactive compounds and their potential for the treatment of neurological disorders.

4. Dubey, A., Ghosh, N. S., Rathor, V. P. S., Patel, S., Patel, B., & Purohit, D. (2022). SARS-CoV-2 infection leads to neurodegenerative or neuropsychiatric diseases.

5. Chandra, D., Yadav, I. K., Jaiswal, D., Ghosh, N., Singh, H. P., Mishra, A., … (Year not specified). Formulation and evaluation of satranidazole microspheres for colon-targeted drug delivery.

Nayeralsadat Fatemi | Oncology | Best Researcher Award

Published on by Health Scientists

Dr. Nayeralsadat Fatemi | Oncology | Best Researcher Award 

Researcher | Research Institute for Gastroenterology and Liver Diseases | Iran

Dr. Nayeralsadat Fatemi is a distinguished Research Scientist at the Research Institute for Gastroenterology and Liver Diseases (RIGLD), Tehran, Iran, with a profound background in genetics and molecular medicine. She obtained her B.Sc. in Genetics from Esfahan University in 2007, followed by an M.Sc. in Genetics from Shahrekord University in 2012, and earned her Ph.D. in Molecular Medicine from Zanjan University of Medical Sciences in 2020. Dr. Fatemi’s research primarily focuses on colorectal cancer, gastrointestinal disorders, reproductive genetics, and the interplay between microbiota and cancer-related molecular pathways. Her work integrates genomics, transcriptomics, and bioinformatics analyses to uncover biomarkers, drug resistance mechanisms, and potential therapeutic targets. She has contributed to over thirty peer-reviewed publications in high-impact journals, including Gut Pathogens, Virulence, Expert Reviews in Molecular Medicine, Digestive Diseases and Sciences, and International Journal of Cancer, with notable studies on Fusobacterium nucleatum in colorectal cancer, microRNA-mediated regulatory networks, and genetic causes of recurrent pregnancy loss. Dr. Fatemi has presented her findings at numerous national and international conferences, earning recognition for excellence in research communication, including Best Poster awards at reproductive medicine congresses. Beyond her research contributions, she serves as an active reviewer and editorial board member for several scientific journals in molecular medicine, cancer biology, and reproductive genetics, reflecting her commitment to advancing scientific rigor and knowledge dissemination in health sciences. Her career exemplifies a dedication to translational research, bridging fundamental molecular discoveries with clinical applications to improve diagnostics, therapeutics, and patient outcomes in gastroenterology and reproductive medicine. She has 218 citations from 31 documents with an h-index of 7.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Fatemi, N., Tierling, S., Es, H. A., Varkiani, M., Mojarad, E. N., Aghdaei, H. A., … (2022). DNA methylation biomarkers in colorectal cancer: Clinical applications for precision medicine.

2. Fatemi, N., Sanati, M. H., Shamsara, M., Moayer, F., Zavarehei, M. J., Pouya, A., … (2014). TBHP-induced oxidative stress alters microRNAs expression in mouse testis. Journal of Assisted Reproduction and Genetics.

3. Amiri Yekta, A., Dalman, A., Eftekhari-Yazdi, P., Sanati, M. H., Shahverdi, A. H., … (2013). Production of transgenic goats expressing human coagulation factor IX in the mammary glands after nuclear transfer using transfected fetal fibroblast cells.

4. Fatemi, N., Sanati, M. H., Jamali Zavarehei, M., Ayat, H., Esmaeili, V., … (2013). Effect of tertiary‐butyl hydroperoxide (TBHP)‐induced oxidative stress on mice sperm quality and testis histopathology.

5. Rejali, L., Seifollahi Asl, R., Sanjabi, F., Fatemi, N., Asadzadeh Aghdaei, H., … (2023). Principles of molecular utility for CMS classification in colorectal cancer management.

Virginie Guastella | Oncology | Best Researcher Award

Published on by Health Scientists

Prof. Dr. Virginie Guastella | Oncology | Best Researcher Award

Associate Professor | University Hospital Clermont-ferrand | France

Dr. Virginie Guastella is a distinguished physician and researcher specializing in palliative care and pain management. She holds a Doctorate in Medicine and an Habilitation à Diriger des Recherches (HDR) focused on opioid analgesics and cancer pain. She currently serves as Head of the Palliative Care Unit at CHU Clermont-Ferrand and as Associate Professor in Palliative Medicine at the University Clermont Auvergne, leading the UIC “Douleur, qualité de vie et maladie grave” within the GRUIC “Douleurs chroniques et thérapeutiques.” Her clinical work emphasizes optimizing pain management, end-of-life care, and therapeutic support for patients with advanced illness, while her research explores critical areas including opioid misuse, the integration of virtual reality and music care in palliative settings, and early detection of chemotherapy-induced neuropathies. She has supervised over 24 medical theses and numerous master-level projects, contributing significantly to clinical education, and is a prolific author with 20 international peer-reviewed publications, multiple national articles, and several book chapters addressing topics from opioid prescribing practices to patient and caregiver experiences in palliative care. Beyond research and clinical responsibilities, she actively participates in national and regional committees, contributes to guideline development, and advocates for palliative medicine education and ethics. Through her combined contributions in research, education, and clinical practice, she has played a pivotal role in advancing patient-centered care, promoting evidence-based practices, and improving the quality of life for patients facing serious illness, establishing herself as a leading figure in palliative care and pain management. She has 485 citations from 41 documents with an h-index of 9.

Profiles: Scopus | ORCID

Featured Publications

1. Lawton, G., Calvel, L., Perceau-Chambard, E., Guastella, V., Economos, G., & Evin, A. (2025). Career trajectories after palliative care training: A national e-survey of medical interns in France.

2. Klaeyle, D., Calvel, L., Perceau-Chambard, E., Guastella, V., Economos, G., & Evin, A. (2025). Teaching palliative medicine in the medical school clerkship in France: A national e-survey.

3. Guastella, V., Lambert, C., Lafforgue, A., Metretin, P., Verstreate, A., Watelet, S., Perceau-Chambard, É., & Lautrette, A. (2024). Withholding or withdrawing life-sustaining treatments in the COVID-19 pandemic.

4. Guastella, V., Delorme, J., Chenaf, C., & Authier, N. (2022). The prevalence of off-label prescribing of transmucosal immediate-release fentanyl in France. Journal of Pain and Symptom Management.

5. Preux, C., Bertin, M., Tarot, A., Authier, N., Pinol, N., Brugnon, D., Pereira, B., & Guastella, V. (2022). Prevalence of opioid use disorder among patients with cancer-related pain: A systematic review.